title: Blood storage duration and biochemical recurrence of cancer after radical prostatectomy.
abstract: OBJECTIVE
  To test the hypothesis that perioperative transfusion of allogeneic and autologous red blood cells (RBCs) stored for a prolonged period speeds biochemical recurrence of prostate cancer after prostatectomy.
  
  
  METHODS
  We evaluated biochemical prostate cancer recurrence in men who had undergone radical prostatectomy and perioperative blood transfusions from July 6, 1998, through December 27, 2007. Those who received allogeneic blood transfusions were assigned to nonoverlapping "younger," "middle," and "older" RBC storage duration groups. Those who received autologous RBC transfusions were analyzed using the maximum storage duration as the primary exposure. We evaluated the association between RBC storage duration and biochemical recurrence using multivariable Cox proportional hazards regression.
  
  
  RESULTS
  A total of 405 patients received allogeneic transfusions. At 5 years, the biochemical recurrence-free survival rate was 74%, 71%, and 76% for patients who received younger, middle, and older RBCs, respectively; our Cox model indicated no significant differences in biochemical recurrence rates between the groups (P=.82; Wald test). Among patients who received autologous transfusions (n=350), maximum RBC age was not significantly associated with biochemical cancer recurrence (P=.95). At 5 years, the biochemical recurrence-free survival rate was 85% and 81% for patients who received younger and older than 21-day-old RBCs, respectively.
  
  
  CONCLUSIONS
  In patients undergoing radical prostatectomy who require RBC transfusion, recurrence risk does not appear to be independently associated with blood storage duration.
authors.affiliation: Department of Outcomes Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
authors.forename: Juan P
authors.initials: JP
authors.lastname: Cata
authors.forename: Eric A
authors.initials: EA
authors.lastname: Klein
authors.forename: Gerald A
authors.initials: GA
authors.lastname: Hoeltge
authors.forename: Jarrod E
authors.initials: JE
authors.lastname: Dalton
authors.forename: Edward
authors.initials: E
authors.lastname: Mascha
authors.forename: Jerome
authors.initials: J
authors.lastname: O'Hara
authors.forename: Amanda
authors.initials: A
authors.lastname: Russell
authors.forename: Andrea
authors.initials: A
authors.lastname: Kurz
authors.forename: Shamgar
authors.initials: S
authors.lastname: Ben-Elihayhu
authors.forename: Daniel I
authors.initials: DI
authors.lastname: Sessler
mesh_terms: D001793:Blood Preservation; D001804:Blood Transfusion, Autologous; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000209:etiology* / Q000401:mortality; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000601:surgery*; D015996:Survival Rate; D013997:Time Factors; D065227:Transfusion Reaction; D014481:United States / Q000453:epidemiology
chemical_list: D017430:Prostate-Specific Antigen